← Back to Search

Exercise for Type 2 Diabetes (RESIST Trial)

N/A
Waitlist Available
Led By Lauren M Sparks, PhD
Research Sponsored by Translational Research Institute for Metabolism and Diabetes, Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 30 to 65 years.
Type 2 diabetes determined by self-report or by a fasting glucose > 126mg/dl
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial is to help researchers understand why some people don't get the benefits of exercise.

Who is the study for?
This trial is for adults aged 30-65 with Type 2 Diabetes, who are not currently exercising regularly. Participants can be on certain diabetes medications like metformin but must stop them during the study. They should have an HbA1c level that reflects moderate blood sugar control and be willing to exercise daily for the study period.
What is being tested?
The trial is studying how exercise affects individuals with Type 2 Diabetes. Researchers want to understand why some people don't get the usual benefits from physical activity. Participants will engage in a prescribed exercise routine throughout the study.
What are the potential side effects?
Since this trial involves exercise as an intervention, potential side effects may include muscle soreness, fatigue, or injury related to physical activity. However, these risks are generally low and manageable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 30 and 65 years old.
Select...
I have type 2 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 10 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in ATPmax
Secondary study objectives
Change in in vivo and in vitro mitochondrial function
Other study objectives
Promoter methylation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExerciseExperimental Treatment1 Intervention
10 weeks of aerobic exercise
Group II: Active ControlActive Control1 Intervention
Young athletes as a trained control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~820

Find a Location

Who is running the clinical trial?

Translational Research Institute for Metabolism and Diabetes, FloridaLead Sponsor
40 Previous Clinical Trials
3,580 Total Patients Enrolled
American Diabetes AssociationOTHER
143 Previous Clinical Trials
100,994 Total Patients Enrolled
AdventHealth Translational Research InstituteLead Sponsor
50 Previous Clinical Trials
5,880 Total Patients Enrolled

Media Library

Exercise Clinical Trial Eligibility Overview. Trial Name: NCT01911104 — N/A
Type 2 Diabetes Clinical Trial 2023: Exercise Highlights & Side Effects. Trial Name: NCT01911104 — N/A
Type 2 Diabetes Research Study Groups: Exercise, Active Control
Exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT01911104 — N/A
~7 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top